[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351782-105":59,"doc-detail-351782-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","an-integrated-analysis-of-slc7a11-as-a-pan-cancer-immunotherapeutic-biomarker-with-experimental-validation-of-its-regulation-by-mir-148b-3p-in-breast-cancer","An integrated analysis of SLC7A11 as a pan-cancer immunotherapeutic biomarker with experimental validation of its regulation by miR-148b-3p in breast cancer","","Identifying reliable biomarkers for immunotherapy response remains challenging. This study integrates pan-cancer transcriptomic analyses to characterize SLC7A11, a regulator of redox homeostasis and ferroptosis, and evaluates links with immunotherapy-related features and survival. Using TCGA and GTEx, it tests associations with TMB, MSI, PD-L1, and immune infiltration, and highlights improved immunotherapy response but worsened prognosis in most tumors, including breast cancer. In triple-negative breast cancer models, miR-148b-3p is shown to downregulate SLC7A11, modulating glutathione, lipid peroxidation, and ferroptosis-associated survival, supporting an immune- and ferroptosis-centered biomarker hypothesis.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/an-integrated-analysis-of-slc7a11-as-a-pan-cancer-immunotherapeutic-biomarker-with-experimental-validation-of-its-regulation-by-mir-148b-3p-in-breast-cancer/351782/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/an-integrated-analysis-of-slc7a11-as-a-pan-cancer-immunotherapeutic-biomarker-with-experimental-validation-of-its-regulation-by-mir-148b-3p-in-breast-cancer/351782.png","ImageObject",300,407,{"name":92,"@type":93},"Dipper","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are biomarkers for immunotherapy response difficult to identify?","Question",{"text":112,"@type":113},"Immune checkpoint inhibitors show moderate efficacy across many cancer types, and overall response rates can be very low for a substantial fraction of cancers. This makes predictive implementation a major challenge.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was SLC7A11 analyzed across cancers in this study?",{"text":117,"@type":113},"SLC7A11 expression was systematically assessed across cancer types using TCGA and GTEx data, and its associations with immunotherapy-related features were evaluated, followed by survival analyses in general and immunotherapy-treated cohorts.",{"name":119,"@type":110,"acceptedAnswer":120},"What role does miR-148b-3p play in triple-negative breast cancer?",{"text":121,"@type":113},"In TNBC cell models, in vitro experiments support that miR-148b-3p negatively regulates SLC7A11. Higher SLC7A11 corresponds to increased glutathione, reduced lipid peroxidation, and enhanced survival under ferroptosis-inducing conditions.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351782,1790143573,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374404997633,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","TYPE Original Research PUBLISHED 19 May 2026  \nDOI 10.3389/fimmu.2026.1752767  \nOPEN ACCESS  \nEDITED BY  \nTakaji Matsutani, Anymics Inc., Japan  \nREVIEWED BY  \nHai-Ying Shen,  \nUniversity of Nebraska Medical Center, United States  \nLin Dong Xu,  \nShenzhen University, China  \n*CORRESPONDENCE  \nKaifeng Niu  \n [niukf@big.ac.cn](niukf@big.ac.cn)[ ](niukf@big.ac.cn)Lei Zhang  \n [zhanglei3@dazd.cn](zhanglei3@dazd.cn)  \n†These authors have contributed equally to this work  \nRECEIVED 24 November 2025  \nREVISED 21 April 2026  \nACCEPTED 27 April 2026  \nPUBLISHED 19 May 2026  \nCITATION  \nZhao S, Zheng M, Ma G, Niu K and Zhang L (2026) An integrated analysis of SLC7A11 as a pan-cancer immunotherapeutic biomarker with experimental validation of its regulation by miR-148b-3p in breast cancer.  \nFront. Immunol. 17:1752767 .  \ndoi: 10.3389/fimmu.2026.1752767  \nCOPYRIGHT  \n© 2026 Zhao, Zheng, Ma, Niu and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) .  \nThe use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nAn integrated analysis of SLC7A11 as a pan-cancer immunotherapeutic biomarker with experimental validation of its regulation by miR- 148b-3p in breast cancer  \nSongchen Zhao 1†, Miao Zheng 2†, Guannan Ma 3, Kaifeng Niu 4,5* and Lei Zhang 2,3*  \n1 Department of Medical Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China, 2The First Afﬁliated Hospital of Jinzhou Medical University, Jinzhou, China, 3Zhejiang Key Laboratory of Digital Technology in Medical Diagnostics, Hangzhou, China, 4China National Center for Bioinformation, Beijing, China, 5 Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China  \nBackground: Identifying reliable biomarkers for immunotherapy response remains challenging. Solute carrier family 7 member 11 (SLC7A11), a key regulator of redox homeostasis and ferroptosis, demonstrates signiﬁcant tumor-promoting potential across cancers, yet its pan-cancer associations with immunotherapy-related features and interaction with microRNAs in triplenegative breast cancer pathogenesis remain elusive.  \nMethods: We systematically analyzed SLC7A11 expression across cancer types using TCGA and GTEx data, and evaluated its associations with immunotherapyrelated features. Survival analyses were assessed in general and immunotherapytreated cohorts. A miRNA regulatory network targeting SLC7A11 was constructed in breast cancer and the SLC7A11-miR-148b-3p axis was tested via in vitro experiments in triple-negative breast cancer (TNBC) cell models (MDA-MB-231 and MDA-MB-468) .  \nResults: Pan-cancer analysis revealed upregulation of SLC7A11 transcriptional expression in over 88% tumor types, and associations with established immunotherapy-related features, including tumor mutational burden, microsatellite instability, PD-L1 expression, and immune inﬁltration. Higher SLC7A11 expression was associated with improved response to immunotherapy, but inferior prognosis in most tumors, including breast cancer. In TNBC cell models, in vitro experiments supported that miR-148b-3p negatively regulated SLC7A11, and higher SLC7A11 expression was associated with increased glutathione levels, reduced lipid peroxidation, and enhanced cell survival under ferroptosis-inducing conditions.  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nConclusions: Our pan-cancer analyses reveal a potential biological link between SLC7A11, ferroptosis, and tumor immunity, generating the hypothesis that SLC7A11 may serve as a biomarker for immune checkpoint inhibitor response. In TNBC models, we identify the miR-148b-3p/SLC7A11 axis as a potential regulator o","cbCaiv0KViHpnSD7","https://ap.wps.com/l/cbCaiv0KViHpnSD7","pdf",5510717,11,"English","# Background\n# Methods\n# Results\n# Conclusions\n# Introduction\n# Key findings\n# Keywords","[{\"question\":\"Why are biomarkers for immunotherapy response difficult to identify?\",\"answer\":\"Immune checkpoint inhibitors show moderate efficacy across many cancer types, and overall response rates can be very low for a substantial fraction of cancers. This makes predictive implementation a major challenge.\"},{\"question\":\"How was SLC7A11 analyzed across cancers in this study?\",\"answer\":\"SLC7A11 expression was systematically assessed across cancer types using TCGA and GTEx data, and its associations with immunotherapy-related features were evaluated, followed by survival analyses in general and immunotherapy-treated cohorts.\"},{\"question\":\"What role does miR-148b-3p play in triple-negative breast cancer?\",\"answer\":\"In TNBC cell models, in vitro experiments support that miR-148b-3p negatively regulates SLC7A11. Higher SLC7A11 corresponds to increased glutathione, reduced lipid peroxidation, and enhanced survival under ferroptosis-inducing conditions.\"}]","An integrated analysis of SLC7A11 as a pan-cancer immunotherapeutic biomarker with experimental validation of its regulation by miR-148b-3p in breast cancer | PDF",1790095872,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2946cf43499db456dc3e1c1ea6e105a8.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a15109a98a8c56827107c42218bf381.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/09a7a68784ad5f19852ff6df76230bba.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/50cdbe7b9405b4f1e53e5e2a3706f486.webp",980,1385]